Hematologic Neoplasms

• 

  Subject Areas on Research

  • A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. 
  • A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. 
  • A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. 
  • Addressing End-of-Life Quality Gaps in Hematologic Cancers: The Importance of Early Concurrent Palliative Care. 
  • Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. 
  • Alemtuzumab for the prevention and treatment of graft-versus-host disease. 
  • Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. 
  • Apoptosis in haematological malignancies. 
  • B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. 
  • B cells in chronic graft-versus-host disease. 
  • Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review. 
  • Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. 
  • Cancer and pregnancy: the clinician's perspective. 
  • Carcinogenicity of gasoline: a review of epidemiological evidence. 
  • Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study. 
  • Clinical utility of computed tomography screening of chest, abdomen, and sinuses before hematopoietic stem cell transplantation: the St. Jude experience. 
  • Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. 
  • Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. 
  • Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors. 
  • Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. 
  • Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. 
  • Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. 
  • Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. 
  • Ibrutinib: a new targeted therapy for hematologic cancers. 
  • Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies. 
  • Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. 
  • Linker for activation of T cells (LAT), a novel immunohistochemical marker for T cells, NK cells, mast cells, and megakaryocytes: evaluation in normal and pathological conditions. 
  • Malignant (Diffuse) Mesothelioma in Patients With Hematologic Malignancies: A Clinicopathologic Study of 45 Cases. 
  • Management of adverse events associated with idelalisib treatment: expert panel opinion. 
  • Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. 
  • Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. 
  • Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment. 
  • One-unit versus two-unit cord-blood transplantation for hematologic cancers. 
  • One-unit versus two-unit cord-blood transplantation. 
  • Palliative care and hematologic malignancies: old dog, new tricks? 
  • Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. 
  • Perceptions of palliative care among hematologic malignancy specialists: a mixed-methods study. 
  • Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. 
  • Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. 
  • Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies. 
  • Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. 
  • Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. 
  • Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. 
  • Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. 
  • Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. 
  • Prevention of GVHD without losing GVL effect: windows of opportunity. 
  • RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. 
  • Randomized clinical trials for hematopoietic stem cell transplantation: lessons to be learned from the European experience. 
  • Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. 
  • Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. 
  • Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies. 
  • Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002). 
  • Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors. 
  • Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. 
  • Role of transforming growth factor-beta in hematologic malignancies. 
  • Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors. 
  • Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials. 
  • T-Cell recovery in adults and children following umbilical cord blood transplantation. 
  • The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review. 
  • The Use of Indwelling Tunneled Pleural Catheters for Recurrent Pleural Effusions in Patients With Hematologic Malignancies: A Multicenter Study. 
  • The copper chelator ATN-224 induces peroxynitrite-dependent cell death in hematological malignancies. 
  • The relationship between methylenetetrahydrofolate reductase polymorphism and hematological malignancy. 
  • The vascular niche: home for normal and malignant hematopoietic stem cells. 
  • Thioredoxin and hematologic malignancies. 
  • Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. 
  • Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. 
  • Tumor selective G2/M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22, a benzazepine. 
  • Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. 
  • Venous Thromboembolism Risk Assessment and Prophylaxis Use in Pediatric, Adolescent, and Young Adult Hematology Oncology Patients. 
  • Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. 
  • What is different about patients with hematologic malignancies? A retrospective cohort study of cancer patients referred to a hospice research network. 
  • When and why should patients with hematologic malignancies see a palliative care specialist? 
• 

  Keywords of People

  • Barfield, Raymond Carlton, Associate Professor of Pediatrics, Duke Science & Society
  • Brennan, Todd Victor, Associate Professor of Surgery, Surgery, Abdominal Transplant Surgery
  • Chen, Jun, Associate Professor of Medicine, Duke Cancer Institute
  • Craciunescu, Oana, Associate Professor of Radiation Oncology, Radiation Oncology
  • Dement, John McCray, Professor Emeritus in Community and Family Medicine, Community and Family Medicine, Occupational & Environmental Medicine
  • Doan, Phuong Linh, Assistant Professor of Medicine, Duke Cancer Institute
  • Lagoo, Anand Shreeram, Professor of Pathology, Pathology
  • LeBlanc, Thomas William, Associate Professor of Medicine, Duke Cancer Institute
  • Parikh, Suhag H., Associate Professor of Pediatrics, Pediatrics, Blood and Marrow Transplantation
  • Tsalik, Ephraim, Associate Professor of Medicine, Molecular Genetics and Microbiology
  • Yang, Yiping, Professor of Medicine, Immunology